US › Healthcare

Evolus Inc (EOLS)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$6.12+1.16%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$73.1M
Revenue YoY
+6.7%
Net profit
$-10.7M
Profit YoY
+43.5%
EPS
$-0.05
EPS estimate
$-0.12
Net margin
-14.6%

EPS came in at -0.05 against a street estimate of -0.12 — a beat of 58.3%.

Key statistics

Market cap
$398.4M
Forward P/E
53.2
P/B
53.71
Book value
$-0.44
EPS (TTM)
$-0.66
52-week high
$9.15
52-week low
$3.86
50-day MA
$6.46
200-day MA
$5.88
Beta
1.36

Analyst view

Analysts rate Evolus Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $14.67.

Shareholding

Insiders
14.68%
Institutions
70.57%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC9.68%
BlackRock Inc6.51%
BRAIDWELL LP4.72%
Frazier Life Sciences Management, L.P.3.99%
Vanguard Capital Management, LLC3.75%
Soleus Capital Management, L.P.3.41%
Stonepine Capital Management Llc2.67%
Millennium Management LLC2.22%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Evolus Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.